The in vitro effects of interferon-gamma, alone or in combination with amphotericin B, tested against the pathogenic fungi *Candida albicans* and *Aspergillus fumigatus*

Moufid El-Khoury¹, Rogine Ligot¹, Simon Mahoney¹, Colin M. Stack¹, Gabriel G. Perrone¹ and C. Oliver Morton¹,２*

### Abstract

**Objective:** Recent studies into the antifungal activity of NK-cells against the *Aspergillus fumigatus* have presented differing accounts on their mode of antifungal activity. One of these mechanisms proposed that NK-cells may kill the fungus via the direct effects of exposure to Interferon gamma (IFN-γ).

**Results:** In this study we investigated the direct antifungal effects of recombinant human IFN-γ against a range of pathogenic fungi by measuring cellular damage using an XTT-based assay and cell viability through plate counts. It was found that 32 pg/ml of IFN-γ exhibited a significant but small antifungal effect on *A. fumigatus* (*p* = 0.02), *Aspergillus flavus* (*p* = 0.04) and *Saccharomyces cerevisiae* (*p* = 0.03), inhibiting growth by 6, 11 and 17% respectively. No significant inhibitory effects were observed in *Candida* species (*p* > 0.05 for all species tested) or *Cryptococcus neoformans* (*p* = 0.98). Short term exposure (3 h) to a combination of amphotericin B (1 µg/ml) and IFN-γ (32 pg/ml) increased the effectiveness of amphotericin B against *A. fumigatus* and *S. cerevisiae* but not *Candida albicans*. These data suggest that IFN-γ does not possess strong antifungal activity but can enhance the effect of amphotericin B under some testing conditions against *Aspergillus* species.

**Keywords:** Amphotericin B, Interferon-gamma, Antifungals, Aspergillosis

### Introduction

Invasive aspergillosis (IA) is a life-threatening fungal disease of individuals undergoing immunosuppressive treatments such as transplants or those with predisposing conditions such as advanced AIDS [1, 2]. Despite current treatment methods the mortality rate is as high as 40% and the number of effective antifungal agents available is limited due to the similarity between fungal and mammalian cells. Antifungal drug resistance, particularly to azoles, is also increasing which has made it imperative to identify novel antifungal therapies and drug targets [3].

The immune response to IA has received a lot of attention and it has been shown that immune reconstitution and immunomodulation are necessary for effective treatment of IA [4]. In neutropenic patients the activity of cytokines is essential for determining the outcome of IA, with proinflammatory cytokines being of prime importance. Interferon-gamma (IFN-γ) is a proinflammatory cytokine with an important role in immunity against IA, and in neutropenic mice its secretion by natural killer cells (NK-cells) was found to be essential for defense against the fungus [5].

The importance of IFN-γ has led to its use as a therapeutic intervention in IA, with several studies assessing the potential of IFN-γ alone or in combination with antifungal drugs to treat IA [6, 7]. In a review of case studies it was found that immunotherapy with IFN-γ could
restore immune function and aid in the treatment of fungal sepsis [8]. In experimental models of cryptococcosis the administration of IFN-γ was weakly effective but it was highly effective in combination with amphotericin B [9]. Thus combined treatment with antifungals and immunotherapy may be a promising strategy to improve treatments against IA. Interestingly, data from a study of the in vitro interaction between NK-cells with Aspergillus fumigatus indicated that IFN-γ might be responsible for NK-cell mediated killing of A. fumigatus [10]. However, this antifungal activity of IFN-γ was not observed in another interaction study between NK-cells and A. fumigatus [11], which implicated perforin and granzyme in the killing of A. fumigatus by NK-cells.

**Main text**

The purpose of this study was to answer the question arising from these interactions studies; does IFN-γ have significant antifungal activity? Furthermore, this study also examined if addition of IFN-γ could enhance the activity of antifungal drugs in vitro?

**Organisms and strains**

The strains used in this study were Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Cryptococcus neoformans, A. fumigatus, Aspergillus flavus and Aspergillus clavatus; clinical isolates obtained from the culture collection at Westmead Hospital (Sydney, Australia). Saccharomyces cerevisiae strain BY4742 was used in this study (Thermo Fisher). The fungi were maintained on potato dextrose agar and defined inocula were prepared as previously described [12].

**Measurement of fungal metabolic activity**

The XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) metabolic assay was used to assess metabolic inhibition caused by recombinant IFN-γ (R & D Systems) as previously described [10]. How- ever, this antifungal activity of IFN-γ was not observed from the culture collection at Westmead Hospital (Sydney, Australia).

**Fig. 1**

A Measurement of inhibition caused by treatment with IFN-γ on several pathogenic fungi using the XTT assay. The results were expressed as the percentage of the metabolic activity of treated cells compared to untreated cells. The absorbance reading at OD₄₉₂ for the untreated control for each species was taken as 100%; the mean OD₄₉₂ value was 0.44 (±0.07). The data shown are means and standard errors of the growth inhibition (treated/untreated control) from three replicate experiments. Data were analysed by t-test to compare low to high doses of IFN-γ (*p < 0.05, **p < 0.01, ***p < 0.001). p-values for each test are shown in the figure. B Measurement of inhibition caused by incubation of several pathogenic fungi with IFN-γ using the XTT assay over an extended dose range. No significant differences in fungal survival were found when treatment with 32 pg/ml to treatment with 50 or 100 pg/ml of IFN-γ were compared. Data in 1B were analysed by one-way ANOVA (p-value shown in the figure) and Dunn’s post-test (p-values shown as asterisks) to compare the range of doses of IFN-γ (*p < 0.05, **p < 0.01, ***p < 0.001). Asterisks indicate that doses are significantly different to the lowest dose.

**CFU counts**

Cultures containing final concentrations of approx. 5 × 10⁴ colony forming units (C.F.U.)/ml of S. cerevisiae, C. albicans and A. fumigatus with combinations of IFN-γ (32 pg/ml) and amphotericin B (1 or 2 µg/ml) were prepared. These fungi were tested because A. fumigatus and S. cerevisiae were sensitive and C. albicans was relatively resistant to IFN-γ in XTT assays. These were incubated for 3 h to avoid hyphal development in A. fumigatus, after incubation serial dilutions of each culture were prepared and plated onto YPD agar; these were incubated at 30 °C for S. cerevisiae and 37 °C for the other fungi for two days followed by counting of C.F.U.

**MIC determinations**

Yeast Sensititre Plate YO10 (Thermo Scientific) is a microdilution method that was used in this study to determine the MIC of common antifungal drugs against selected fungi. The tests were performed as per the manufacturer’s instructions for plates without IFN-γ. For plates including IFN-γ; IFN-γ was added to the YeastOne inoculum broth to yield a final concentration of 32 pg/ml. Fungal cells were then added to the broth as described in the manufacturer’s instructions to achieve an organism density of 1.5–8 × 10³ cells/ml; 100 µl of broth containing cells and IFN-γ was added to each well of the YO10 Sensititre plate. After inoculation the plates were incubated at 37 °C for 24 h. These tests were performed three times. The YO10 Sensititre plate contains the following drugs (concentration range): Amphotericin B (0.12–8 µg/ml), Anidulafungin (0.015–8 µg/ml), Caspofungin
El-Khoury et al. BMC Res Notes (2017) 10:364

(0.008–8 µg/ml), Fluconazole (0.12–256 µg/ml), 5-Fluorocytosine (0.06–64 µg/ml), Itraconazole (0.015–16 µg/ml), Micafungin (0.008–8 µg/ml), Posaconazole (0.008–8 µg/ml), Voriconazole (0.008–8 µg/ml).

Statistical analysis
The effects IFN-γ on pathogenic fungi were analysed by two-tailed t test (XTT assay, Fig. 1A) or one–way ANOVA with Dunn’s post-test (Figs. 1B, 2) using Graphpad Prism Version 5.02 for Windows (Graphpad Software, San Diego, CA, USA).

This study examined the antifungal potential of IFN-γ alone or in combination with amphotericin B against pathogenic fungi in vitro. The data for short term exposure (3 h) (Figs. 1A, 2) was compatible with in vivo studies showing that the combination could be more effective than a single agent [9].

The direct antifungal effects of IFN-γ on pathogenic fungi
Testing the antifungal activity of IFN-γ on nine fungi revealed significant sensitivity in A. fumigatus (p = 0.02), A. flavus (p = 0.04) and the non-pathogen S. cerevisiae (p = 0.03) to 32 pg/ml (Fig. 1A), which agreed with previous findings for A. fumigatus [10] and C. albicans [13]. This quantity is higher than the plasma IFN-γ concentrations of ca. 20 pg/ml reported for individuals with severe infection [14], however during immunotherapy serum levels of IFN-γ can rise to over 100 pg/ml for periods of up to 12 h after administration of a dose of 100 µg/m² [15], which is the dosage used in cases using IFN-γ to treat IA [8]. The other fungi that were tested were unaffected by these concentrations of IFN-γ and were even resistant to higher concentrations (up to 100 pg/ml) (Fig. 1B). No significant differences were observed between treatment with 32 pg/ml and treatments with 50 pg/ml or 100 pg/ml; although there was a trend for increased killing with increased dose for A. fumigatus and A. clavatus (Fig. 1B).

The limited antifungal toxicity of IFN-γ suggests that it is not the sole mechanism of NK-cell mediated antifungal activity and that perforin-mediated cytotoxicity is a more convincing candidate [11]. The perforin–granzyme system is an established mechanism of inducing death in target cells, whereas IFN-γ is an established
immunoregulator. There is evidence that NK cell-derived IFN-γ is an essential component of host defence against invasive aspergillosis in neutropenic mice [5]. This was determined when depletion of NK-cells from murine lungs resulted in increased fungal load independent of the presence of T and B cells [5]. The role of IFN-γ in these mice was proposed to be due to stimulation of macrophages and cytokine production that modulated the immune system to enable an effective antifungal response, which was also a component of in NK-cell mediated activity against Candida [13]. However, it has been observed that IFN-γ expression by NK-cells was reduced by the presence of A. fumigatus [11] and Rhizopus oryzae [16], indicating that the role of IFN-γ in NK-cell interactions with moulds may be complex.

The effects of combined amphotericin B and IFN-γ treatment

A combination of amphotericin B and IFN-γ induced greater direct antifungal activity than amphotericin B or IFN-γ alone (Fig. 2); this was particularly significant for S. cerevisiae (p < 0.001) and A. fumigatus (p = 0.002). A. fumigatus showed less sensitivity than the other two fungi after 3 h exposure to amphotericin B (2 µg/ml); but showed a significant effect when exposed to combinations of IFN-γ (32 pg/ml) and amphotericin B (1 µg/ml and 2 µg/ml).

Amphotericin B was chosen since it is an important fungicide for treating invasive mycoses and because it is a membrane targeting molecule. In the absence of immune cells it was interesting that IFN-γ appeared to enhance the activity of amphotericin B against the fungi tested (Fig. 2). Amphotericin B is proposed to act by causing the formation of pores in target membranes. A molecule with a similar mode of action is the toxin listeriolysin O (LLO) from Listeria monocytogenes; the activity of LLO against human cells has been found to be enhanced by IFN-β [17]. This could provide an avenue to further understand the increased activity of IFN-γ and amphotericin B against some fungi.

However, these data were not supported by combining IFN-γ with the antifungals on sensittitre YO10 plates (Table 1). There was no significant change in the MICs for A. fumigatus or C. albicans other than MIC for fluconazole against C. albicans was reduced from 16 to 4 µg/ml. This difference between C.F.U. counts and Sensititre data is probably because the Sensititre readings were taken after 24 h growth, in that period any influence of IFN-γ may have been masked by the drug. This is similar to the effect seen for S. cerevisiae where treatment with 2 µg/ml amphotericin B caused complete inhibition as did treatment with 2 µg/ml amphotericin and IFN-γ; therefore no differences could be detected between the two treatments (Fig. 2).

In answer to the initial questions posed in this study: IFN-γ weakly fungicidal against some Aspergillus species and S. cerevisiae. This antifungal activity is not sufficient to suggest that it would be the primary factor in NK-cell mediated fungal killing but may play a role in a more complex process that would require further study including NK-cells.

Secondly there is evidence that IFN-γ can enhance the activity of amphotericin B in vitro but this varied between fungi and experimental conditions. The data from this study do not contradict the paradigm that IFN-γ in antifungal therapy acts as an immunomodulator [8]. However, the differential responses of the fungi tested against combination therapy with IFN-γ and amphotericin B indicates a path to study differences in cell wall and membrane composition that might be exploited for the development of targeted antifungals.

Limitations

To conclusively determine the mechanism of NK-cell activity against fungi is beyond the scope of this study. We cannot determine the complete significance of IFN-γ in the context of complex intercellular interactions but show that it is not the sole mechanism of antifungal activity.

Extended exposure times and high drug concentrations in the Sensititre tests may have masked the effect of combined treatment with IFN-γ and antifungals. Much more detailed study is required to fully examine the nature of any enhancement of amphotericin B activity by IFN-γ.

### Table 1 MIC data for Aspergillus fumigatus and Candida albicans inoculated into Sensititre YO10 plates plus or minus 32 pg/ml interferon-γ

| Drug                  | A. fumigatus |                  | C. albicans |                  |
|-----------------------|--------------|-----------------|-------------|-----------------|
|                       | Plus IFN-γ   | Minus IFN-γ     | Plus IFN-γ  | Minus IFN-γ     |
| Anidulafungin         | 2            | 2               | 0.015       | 0.03            |
| Micafungin            | 1            | 1               | 0.015       | 0.015           |
| Caspofungin           | 2            | 2               | 0.06        | 0.12            |
| Fluconazole           | 64           | 64              | <0.06       | <0.06           |
| Posaconazole          | 0.5          | 1               | 1           | 1               |
| Voriconazole          | 0.25         | 0.5             | 0.12        | 0.25            |
| Itraconazole          | 0.25         | 0.25            | 0.25        | 0.5             |
| Fluconazole           | 256          | 256             | 4           | 16              |
| Amphotericin          | 0.5          | 1               | 0.5         | 0.5             |

* MIC values in italic indicate a significant difference.
**Abbreviations**

MIC: minimum inhibitory concentration; IFN-γ: interferon gamma; LLO: listeriolysin O.

**Authors’ contributions**

MEK, RL, and SM performed the experimental work for the study. CS assisted in experimental design and preparation of the manuscript. GP assisted in experimental design, analysis and manuscript preparation. COM designed the study and assisted in data analysis. MEK and OM wrote the manuscript. All authors read and approved the final manuscript.

**Author details**

1 School of Science and Health, Western Sydney University, Building 21 Campbelltown Campus, Narellan Road, Campbelltown, NSW 2560, Australia.

2 School of Science and Health, Western Sydney University, Locked Bag 1797, Penrith, NSW 2571, Australia.

**Acknowledgements**

The authors also would like to thank Val Barrow for technical support and Dr Catrina Halliday at Westmead Hospital for the provision of fungal isolates.

**Competing interests**

The authors declare that they have no competing interests.

**Availability of data and materials**

The data supporting the results of this study are included within this article; raw data can be requested from the corresponding author.

**Consent to publish**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Funding**

Funding from Western Sydney University enabled Mofuid El-Khoury and Rogine Ligot to undertake this research.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Received: 5 February 2017 Accepted: 26 July 2017 Published online: 01 August 2017**

**References**

1. Calton EA, Le Doare K, Appleby G, Chisholm JC, Sharland M, Ladhani SN, Participants C. Invasive bacterial and fungal infections in paediatric patients with cancer: incidence, risk factors, aetiology and outcomes in a UK regional cohort 2009–2011. Pediatr Blood Cancer. 2014;61(7):1239–45.

2. Munoz P, Ceron I, Valero M, Palomo J, Villa A, Eivoro A, Fernandez-Yanez J, Guinea J, Bouza E. Invasive aspergillosis among heart transplant recipients: a 24-year perspective. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2014;33(3):278–88.

3. Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis. 2013;26(6):493–500.

4. Armstrong-James D, Harrison TS. Immunotherapy for fungal infections. Curr Opin Microbiol. 2012;15(4):434–9.

5. Park SJ, Hughes MA, Burdick M, Strierer RM, Mehrad B. Early NK cell-derived IFN-γ (gamma) is essential to host defense in neutropenic invasive aspergillosis. J Immunol. 2009;182(7):4306–12.

6. Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freiheich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RE. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006;106(12):2664–71.

7. Armstrong-James D, Teo IA, Shrivastava S, Petrou MA, Taube D, Dorling A, Shaunik S. Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(8):1796–803.

8. Delsing CE, Gresnigt MS, Leentjens J, Preijers F, Frager FA, Kox M, Monneret G, Venet F, Bleecker-Rovers CP, van de Veerdonk FL, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis. 2014;14:166.

9. Lutz JE, Clemmons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrobial Chemother. 2000;46(3):437–42.

10. Bouzani M, Ok M, McCormick A, Ebel F, Kurzai O, Morton CO, Einsele H, Loeffler J. Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-gamma release. J Immunol. 2011;187(3):1369–76.

11. Schmidt S, Tramsen L, Hanisch M, Latge JP, Huenecke S, Koehl U, Lehrnbecher T. Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia. J Infect Dis. 2011;203(3):430–5.

12. Morton CO, Loeffler J, De Luca A, Frost S, Kenny C, Duval S, Romani L, Rogers TR. Dynamics of extracellular release of Aspergillus fumigatus DNA and galactomannan during growth in blood and serum. J Med Microbiol. 2010;59(Pt 4):408–13.

13. Voigt J, Hunninger K, Bouzani M, Jacobsen ID, Barz D, Hube B, Loffler J, Kurzai O. Human natural killer cells acting as phagocytes against Candida albicans and mounting an inflammatory response that modulates neutrophil antifungal activity. J Infect Dis. 2014;209(4):616–26.

14. Bjerré A, Brusletto B, Holby EA, Kierulf P, Brandtzæg P. Plasma interferon-gamma and interleukin-10 concentrations in systemic meningococcal disease compared with severe systemic Gram-positive septic shock. Crit Care Med. 2004;32(2):433–8.

15. Turner PK, Houghton JA, Petak I, Tillman DM, Douglas L, Schwartzberg LR, Billups CA, Panetta JC, Stewart CF. Interferon-gamma pharmacokinetics in patients with colorectal cancer. Cancer Chemother Pharmacol. 2004;53(3):253–60.

16. Schmidt S, Tramsen L, Perkhofer S, Lass-Floerl C, Hanisch M, Roger F, Klingebiel T, Koehl U, Lehrnbecher T. Rhizopus oryzae hyphae are damaged by human natural killer (NK) cells but suppress NK cell-mediated immunity. Immunobiology. 2013;218(7):939–44.

17. Zwaverink H, Stockinger S, Hazemi P, Lemmens-Gruber R, Deckter T. IFN-gamma increases listeriolysin O-induced membrane permeabilization and death of macrophages. J Immunol. 2006;176(10):4116–23.